undamentalytics Newsletter
Sign in

Cardiff Oncology, Inc. income statement

In fiscal 2025, Cardiff Oncology, Inc. reported revenue of $593,000, down 13.2% on the year before, operating income of −$49.0m (a -8256.3% margin) and net income of −$45.9m, or −$0.69 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0000001000000111
Cost of revenue———012210———————
Gross profit———0−0−1−1−00———————
Research and development12471115881111172733373526
Selling, general and administrative237———14868121313121417
Selling and marketing———3612——————————
General and administrative———6811——————————
Operating income−3−5−11−15−25−40−26−17−17−19−29−40−45−49−49−42
Interest expense0—012210000—————
Net interest income———−1−1−1——————————
Income before tax—————————————−45−46—
Income tax——0000000000000—
Net income−2−12−12−14−27−39−25−16−16−19−28−39−41−45−46−40
Diluted EPS−$0.05−$0.18−$0.14−$0.18−$0.24−$0.27−$10.35−$8.26−$2.80−$1.08−$0.73−$0.89−$0.93−$0.95−$0.69−$0.59
Diluted shares (average)49m65m85m95m132m151m2m2m6m21m39m44m45m48m67m68m
EBITDA−3−5−11−15−25−39−24−16−16−19−28−40−45−48−49−42

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CRDF vs CRVOCRDF vs MNOVCRDF vs STTK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cardiff Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cardiff Oncology, Inc.